. Author manuscript; available in PMC: 2015 Apr 1.

Published in final edited form as: Pediatr Infect Dis J. 2014 Apr;33(4):387–392. doi: 10.1097/INF.0000000000000119

Table 3.

Adjusted and unadjusted models for length of stay and total hospital costs among children treated with ceftriaxone in addition to a macrolide relative to ceftriaxone alone.

Ages 1–4 years	Length of stay		Total hospital cost
Ages 1–4 years	Relative Risk (95% CI)	p-value	Cost Ratio (95% CI)	p-value
Unadjusted	1.00 (0.97, 1.03)	0.88	1.08 (1.05, 1.11)	<0.0001
Covariate adjusted	0.98 (0.95, 1.01)	0.31	1.04 (1.01,1.07)	<0.01
Propensity score & covariate adjusted	0.99 (0.96, 1.02)	0.38	1.04 (1.01,1.07)	<0.01
Propensity score matched*	1.02 (0.99, 1.05)	0.32	1.07 (1.03, 1.10)	<.0001
Ages 5–17
Unadjusted	0.96 (0.93, 0.99)	0.01	1.03 (0.99, 1.06)	0.12
Covariate adjusted	0.95 (0.92,0.98)	<0.01	1.01 (0.98, 1.04)	0.60
Propensity score & covariate adjusted	0.95 (0.92, 0.98)	<0.01	1.01 (0.98, 1.04)	0.55
Propensity score matched^*	0.96 (0.93, 0.99)	<0.01	1.01 (0.98,1.04)	0.62

adjusted for unbalanced covariates